Inactive Instrument

AMT HOLDING Share Price

Equities

End-of-day quote Euronext Amsterdam Other stock markets
- ^EUR	-

AMT HOLDING : Amsterdam Molecular Therapeutics Reports Full Year Results 2011	27/04/12	PU
AMT HOLDING : Amsterdam Molecular Therapeutics rondt uitkering bij voorbaat van uniQure certificaten aan AMT aandeelhouders af	26/04/12	PU
AMT HOLDING : Amsterdam Molecular Therapeutics Receives Further Opinion on Glybera® Marketing Authorisation Application	23/04/12	PU
AMT HOLDING : Progenika Receives CE Mark for First DNA Chip to Detect Mutations in Lipoprotein Lipase (LPL) Gene	27/09/10	PR
AMT HOLDING : Obtains License to Amgen's GDNF Gene to Develop Treatment for Parkinson's Disease with AMT's Proprietary Gene Therapy Platform	18/09/08	GL

AMT HOLDING : AMT's Marketing Authorisation Application voor Glybera(R) verloopt op schema	18/08/10
AMT HOLDING : erhält Lizenz für das Amgen-GDNF-Gen zur Entwicklung einer Therapie für Parkinson mit Hilfe der proprietären AMT-Gentherapie-Plattform	18/09/08
AMT HOLDING : gibt positive klinische Zwischenergebnisse für das Hauptprodukt AMT-011 bekannt	30/05/08

Sector

	1st Jan change	Capi.
MODERNA, INC.	+41.79%	54.04B
IQVIA HOLDINGS INC.	-0.56%	41.92B
LONZA GROUP AG	+49.62%	41.96B
CELLTRION, INC.	-7.20%	28.35B
ICON PUBLIC LIMITED COMPANY	+12.59%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	19B
BIO-TECHNE CORPORATION	+6.92%	13B
UNITED THERAPEUTICS CORPORATION	+24.91%	12.19B
MEDPACE HOLDINGS, INC.	+29.60%	12.28B